In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Koninklijke DSM N.V.

http://www.dsm.com/

Latest From Koninklijke DSM N.V.

P&G Ventures Startup Incubator Yields Supplements For Menopause Symptoms

P&G Ventures startup's partnership with venture capital group M13 delivered its first brand, the Kindra four-product, hormone-free menopausal line. Kindra says its products provide relief from the seven symptoms of menopause in a market largely neglected.

Dietary Supplements Commercial

Omega-3 Firms Parse Amarin's Fair Trade Complaint Into Tariff Act Questions

Attorneys for DSM, Pharmavite and Nordic Naturals pose two questions they say the Supreme Court is being asked in Amarin's request for a fair trade investigation. One is whether under Tariff Act, Federal Circuit lacks jurisdiction to review an ITC decision not to investigate? The second concerns an attempt for private enforcement of FDA regulations framed as a complaint to force an investigation under the Tariff Act.

Dietary Supplements Legal Issues

Amarin's Asking ITC To Do FDA's Job, Federal Attorneys Tell Supreme Court

In petition to Supreme Court, Amarin does not assert it makes any fair trade claim "that could be proved without establishing" an FDCA violation, nor does it dispute that its "claims are ultimately premised on allegations that the FDCA was violated," say DoJ solicitor general and ITC counsel.

Legal Issues Dietary Supplements

Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

Orthopedics Surgical Procedures
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Aland (HK) Holding Limited
    • Amyris Brasil Ltda
    • BioCare Copenhagen
    • DSM Biomedical
    • Fortitech, Inc.
    • Glycom A/S
    • Kensey Nash Corporation
    • Koninklijke CSK Food Enrichment C.V.
    • Royal DSM N.V.
    • Tortuga Companhia Zootecnica Agraria
    • Unitech Industries Limited
UsernamePublicRestriction

Register